News

DCC-3116 demonstrated safety and tolerability across various dose levels in patients with solid tumors harboring a RAS or RAF mutation, according to findings from a phase 1/2 trial presented at the 2022 ESMO Congress.

Multiple blood-based biomarkers suggest potential responses to treatment with maintenance avelumab for patients with advanced or metastatic urothelial carcinoma from the phase 3 JAVELIN Bladder 100 trial, according to an exploratory analysis presented at the European Society for Medical Oncology Congress 2022.

After extended follow-up, continued benefit was seen with the combination of lenvatinib and pembrolizumab in patients with advanced endometrial cancer who previously received platinum chemotherapy, updated efficacy and safety findings from the phase 3 Study 309/KEYNOTE-775 trial showed.

Maintenance rucaparib (Rubraca) induced a progression-free survival (PFS) improvement in patients with newly diagnosed ovarian cancer compared with placebo, which was also seen across all prespecified subgroups.

The FDA has approved eflapegrastim-xnst injection for adult patients with non-myeloid malignancies receiving myelosuppressive anti-cancer drugs linked with clinically significant incidence of febrile neutropenia.

Florida Cancer Specialists & Research Institute, LLC welcomes Monique Sajjad, DO.

Research conducted by Florida Cancer Specialists & Research Institute, LLC will be presented at the European Society of Medical Oncology Congress being held this week in Paris, France.

Steven M. Albelda, MD, discusses what he expects the future of chimeric antigen receptor T-cell use in solid tumors to look like.

The HCRN-GU16-260 trial reported results for patients with clear cell renal cell carcinoma who received frontline nivolumab followed by salvage nivolumab/ipilimumab on disease progression.

AMB-05X has been granted fast track designation for the treatment of patients with tenosynovial giant cell tumor of the knee by the FDA.

The “Every Step of the Way” campaign TV spot from Florida Cancer Specialists & Research Institute, LLC received a prestigious Platinum Hermes Award in the annual 2022 Hermes Creative Awards.

Florida Cancer Specialists & Research Institute celebrated the addition of genomic testing capabilities at its Next Generation Sequencing laboratory in Fort Myers last week with a ribbon cutting ceremony.

Findings from the phase 3 ORIENT-31 study shows improved progression-free survival with sintilimab with or without bevacizumab biosimilar injection and chemotherapy in EGFR-mutated non-squamous non-small cell lung-cancer.

The phase 2 MASTER trial of daratumumab, carfilzomib, lenalidomide, and dexamethasone demonstrates the promise of minimal residual disease surveillance in newly diagnosed multiple myeloma with 0 or 1 high-risk cytogenetic abnormalities

Ronald S. Go, MD, discusses what community oncologists should know regarding the guidelines on managing patients with histiocytic neoplasms.

Mark Yarchoan, MD, discusses the current hepatocellular carcinoma space as well as 3 late breaking abstracts that will be presented at the 2022 ESMO Congress.

Pegfilgrastim-fpgk has been approved by the FDA for patients with febrile neutropenia following data which revealed it to have a high degree of similarity with its reference product.

In an interview with Targeted Oncology, Melina Elpi Marmarelis, MD, further discussed the findings revealed from the LACP cohort of the CHRYSALIS-2 study in non–small cell lung cancer.

David Barrington, MD, discusses the next steps for oncologists treating patients with stage 1B, grade 3 endometrial cancer.

Erika P. Hamilton, MD, discusses the background of a phase 1 trial of DS-6000a in patients with advanced renal cell carcinoma and ovarian cancer.

A patient enrolled in the phase 1 NADOM trial of darovasertib alone in non-metastatic uveal melanoma shows early signs of clinical efficacy.

Sacituzumab govitecan demonstrated promising progression-free survival efficacy in patients with HR+/HER2-low and IHC0 status metastatic breast cancer, showing its potential as a future treatment option.

A cohort of a clinical trial of the experimental agent STP705 successfully treated patients with cutaneous basal cell carcinomas, offering an alternative to surgery or other skin cancer treatment.

In patients with BRAF V600-mutated melanoma and central nervous system metastases, treatment with atezolizumab to vemurafenib plus cobimetinib achieved a good intracranial overall response rate. Responses were all achieved with the combination in patients with BRAF wild-type tumors.

David Hong, MD, explains why larotrectinib may be chosen over other TRK inhibitors for the treatment of NTRK fusion-positive lung cancer.

Valencia D. Thomas, MD, MHCM, discusses the unmet needs which remain in the non-melanoma skin cancer space.

The FDA has approved durvalumab for the treatment of patients with locally advanced or metastatic biliary tract cancer.

Treatment with AST-301 will be explored in patients with HER2-low breast cancer in the phase 2 Cornerstone-011 study.